TAVR Market Shifting Into High Gear
Executive Summary
Momentum is building in the burgeoning and rapidly evolving transcatheter aortic valve replacement (TAVR) market. With a growing body of clinical evidence, the potential for expanded indications in lower-risk patients, and more favorable reimbursement on the horizon, the TAVR market is shifting into high gear, with solid, double-digit growth ahead.
You may also be interested in...
TAVR Market: Next-Generation Devices Seek To Optimize Outcomes
The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.
Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.
Novo Mulls What To Do With Wegovy Windfall
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.